<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9328156</article-id><article-id pub-id-type="pmc">2228066</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kylm&#x000c3;&#x000a4;l&#x000c3;&#x000a4;</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Taube</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tammela</surname><given-names>T. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Risteli</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Risteli</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Elomaa</surname><given-names>I.</given-names></name></contrib></contrib-group><aff>Department of Surgery, Tampere University Hospital, Finland.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>76</volume><issue>7</issue><fpage>939</fpage><lpage>942</lpage><abstract><p>Fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy were treated with estramustine and additionally randomized for treatment with clodronate or placebo. Clodronate treatment was started with 5 days intravenous administration (300 mg day[-1]) and followed by oral treatment (1.6 g day[-1]) for 12 months. Skeletal pain relief was only about 10% better in the clodronate than in the placebo group. The results do not support the superiority of combined intravenous and oral treatment with clodronate compared with oral administration only.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00171-0117.tif" xlink:title="scanned-page" xlink:role="939" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00171-0118.tif" xlink:title="scanned-page" xlink:role="940" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00171-0119.tif" xlink:title="scanned-page" xlink:role="941" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00171-0120.tif" xlink:title="scanned-page" xlink:role="942" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

